Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

[1]  P. Reaven,et al.  Lovastatin, nicotinic acid, and rhabdomyolysis. , 1988, Annals of internal medicine.

[2]  J. Tobert.  Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.

[3]  S. Grundy,et al.  Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. , 1988, The New England journal of medicine.

[4]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[5]  K. K. Larson,et al.  Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy. , 1990, Annals of internal medicine.

[6]  K. Hasegawa,et al.  Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 1990, Biochimica et biophysica acta.

[7]  D. Spach,et al.  Rhabdomyolysis associated with lovastatin and erythromycin use. , 1991, The Western journal of medicine.

[8]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[9]  A. Gavazzi,et al.  Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. , 1993, Transplantation proceedings.

[10]  J. D. Karkas,et al.  Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. , 1993, Nephron.

[11]  C. Sirtori,et al.  Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. , 1993, Pharmacology & therapeutics.

[12]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[13]  G. A. Scarborough,et al.  Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein. , 1994, Molecular pharmacology.

[14]  Lisa Anne Hendricks,et al.  Pharmacokinetics of the combination of fluvastatin and gemfibrozil. , 1995, The American journal of cardiology.

[15]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[16]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[17]  G. Schectman,et al.  Dose-Response Characteristics of Cholesterol-Lowering Drug Therapies: Implications for Treatment , 1996, Annals of Internal Medicine.

[18]  T. Leemann,et al.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.

[19]  C. Glueck,et al.  Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone. , 1997, JAMA.

[20]  U. Christians,et al.  Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine‐treated kidney graft patients after multiple doses , 1997, Clinical pharmacology and therapeutics.

[21]  H. Lennernäs,et al.  Pharmacodynamics and Pharmacokinetics of the HMG-CoA Reductase Inhibitors , 1997, Clinical pharmacokinetics.

[22]  B H Arison,et al.  In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[23]  P. Neuvonen,et al.  Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole , 1998, Clinical pharmacology and therapeutics.

[24]  W. Haefeli,et al.  Rhabdomyolysis due to interaction of simvastatin with mibefradil , 1998, The Lancet.

[25]  P. Neuvonen,et al.  Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid , 1998, Clinical pharmacology and therapeutics.

[26]  K. Ochmann,et al.  PHARMACOKINETICS AND DISPOSITION , 1998 .

[27]  S. Hall,et al.  The interaction of diltiazem with lovastatin and pravastatin , 1998, Clinical pharmacology and therapeutics.

[28]  P. Neuvonen,et al.  Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin. , 1998, British journal of clinical pharmacology.

[29]  U. Christians,et al.  Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? , 1998, Pharmacology & therapeutics.

[30]  S. Olson,et al.  Atorvastatin does not Produce a Clinically Significant Effect on the Pharmacokinetics of Terfenadine , 1998, Journal of clinical pharmacology.

[31]  P. Neuvonen,et al.  Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations , 1998, Clinical pharmacology and therapy.

[32]  J. Turgeon,et al.  Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. , 1998, Trends in pharmacological sciences.

[33]  P. Neuvonen,et al.  Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG‐CoA reductase inhibitors , 1998, Clinical pharmacology and therapeutics.

[34]  P. Neuvonen,et al.  Effect of itraconazole on the pharmacokinetics of atorvastatin , 1998, Clinical pharmacology and therapeutics.

[35]  L Fritsche,et al.  Increase in cerivastatin systemic exposure after single and multiple dosing in cyclosporine‐treated kidney transplant recipients , 1999, Clinical pharmacology and therapeutics.

[36]  P. Neuvonen,et al.  PHARMACOKINETICS AND DISPOSITION , 1999 .

[37]  M. Dominiczak,et al.  Efficacy of statin therapy: possible effect of phenytoin , 1999, Postgraduate medical journal.

[38]  L. Ramsay,et al.  Enhanced cholesterol reduction by simvastatin in diltiazem-treated patients. , 1999, British journal of clinical pharmacology.

[39]  Jamie J. Zhao,et al.  Grapefruit juice has minimal effects on plasma concentrations of lovastatin‐derived 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors , 1999, Clinical pharmacology and therapeutics.

[40]  P. Neuvonen,et al.  Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin , 1999, Clinical pharmacology and therapeutics.

[41]  T. Uchiumi,et al.  Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. , 1999, Molecular pharmacology.

[42]  S. Olson,et al.  Erythromycin Coadministration Increases Plasma Atorvastatin Concentrations , 1999, Journal of clinical pharmacology.

[43]  S. Hall,et al.  The interaction of diltiazem with simvastatin , 2000, Clinical pharmacology and therapeutics.

[44]  P. Neuvonen,et al.  Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin , 2000, Clinical pharmacology and therapeutics.

[45]  M. Rieser,et al.  Lack of a Clinically Significant Pharmacokinetic Interaction between Fenofibrate and Pravastatin in Healthy Volunteers , 2000, Journal of clinical pharmacology.

[46]  A. Mazzu,et al.  Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin , 2000, Clinical pharmacology and therapeutics.

[47]  P. Neuvonen,et al.  Plasma concentrations of active simvastatin acid are increased by gemfibrozil , 2000, Clinical pharmacology and therapeutics.

[48]  R. Davidson,et al.  Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells , 2000 .

[49]  P. Neuvonen,et al.  Effect of fluconazole on plasma fluvastatin and pravastatin concentrations , 2000, European Journal of Clinical Pharmacology.

[50]  W. Mück.  Clinical Pharmacokinetics of Cerivastatin , 2000, Clinical pharmacokinetics.

[51]  P. Kollman,et al.  Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[52]  B. H. Stewart,et al.  Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion , 2000, Journal of clinical pharmacology.

[53]  P. Neuvonen,et al.  Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations , 2000, Clinical pharmacology and therapeutics.

[54]  P. Neuvonen,et al.  Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride , 2001, Clinical pharmacology and therapeutics.

[55]  N. Ichimaru,et al.  Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. , 2001, Atherosclerosis.

[56]  Y. Sugiyama,et al.  A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[57]  C. Scripture,et al.  Clinical Pharmacokinetics of Fluvastatin , 2001, Clinical pharmacokinetics.

[58]  M. Ito,et al.  Colesevelam Hydrochloride: A Novel Bile Acid-Binding Resin , 2001, The Annals of pharmacotherapy.

[59]  A. Hartmann,et al.  Bilateral Pharmacokinetic Interaction Between Cyclosporine A and Atorvastatin in Renal Transplant Recipients , 2001, American Journal of Transplantation.

[60]  W. Jaross,et al.  Pharmacokinetics and Pharmacodynamics of Fluvastatin in Heart Transplant Recipients Taking Cyclosporine A , 2001, Journal of cardiovascular pharmacology and therapeutics.

[61]  J. S. Wang,et al.  Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[62]  James P. Wilson,et al.  Rhabdomyolysis and HMG-CoA Reductase Inhibitors , 2001, The Annals of pharmacotherapy.

[63]  P. Neuvonen,et al.  Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate , 2001, Clinical pharmacology and therapeutics.

[64]  T. Abe,et al.  Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.

[65]  A. Dane,et al.  The effect of fluconazole on the pharmacokinetics of rosuvastatin , 2002, European Journal of Clinical Pharmacology.

[66]  C. Fichtenbaum,et al.  Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047 , 2002, AIDS.

[67]  P. Neuvonen,et al.  Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[68]  James P. Wilson,et al.  FDA Adverse Event Reports on Statin-Associated Rhabdomyolysis , 2002, The Annals of pharmacotherapy.

[69]  A. Manginas,et al.  Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine , 2002, Transplantation.

[70]  J. Feely,et al.  Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors , 2002, Clinical pharmacokinetics.

[71]  G. Amsden,et al.  A Study of the Interaction Potential of Azithromycin and Clarithromycin with Atorvastatin in Healthy Volunteers , 2002, Journal of clinical pharmacology.

[72]  R. Subramanian,et al.  Effects of fibrates on metabolism of statins in human hepatocytes. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[73]  Jennie Chang,et al.  Cerivastatin and reports of fatal rhabdomyolysis. , 2002, The New England journal of medicine.

[74]  B. Ma,et al.  Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[75]  B. Ma,et al.  Mechanistic studies on metabolic interactions between gemfibrozil and statins. , 2002, The Journal of pharmacology and experimental therapeutics.

[76]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[77]  J. Lewin,et al.  Rhabdomyolysis with Concurrent Atorvastatin and Diltiazem , 2002, The Annals of pharmacotherapy.

[78]  W. März,et al.  Risk for myopathy with statin therapy in high-risk patients. , 2003, Archives of internal medicine.

[79]  P. Neuvonen,et al.  Gemfibrozil considerably increases the plasma concentrations of rosiglitazone , 2003, Diabetologia.

[80]  Paul D. Martin,et al.  The effect of erythromycin on the pharmacokinetics of rosuvastatin , 2003, European Journal of Clinical Pharmacology.

[81]  G. Shorten,et al.  The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam , 2003, Anaesthesia.

[82]  Paul D. Martin,et al.  Effect of itraconazole on the pharmacokinetics of rosuvastatin , 2003, Clinical pharmacology and therapeutics.

[83]  Paul D. Martin,et al.  An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. , 2003, Clinical therapeutics.

[84]  A. Åsberg.  Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients. , 2003, Drugs.

[85]  P. Neuvonen,et al.  Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide , 2003, Diabetologia.

[86]  B. Ma,et al.  The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6. , 2003, British journal of clinical pharmacology.

[87]  P. Neuvonen,et al.  Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid , 2004, European Journal of Clinical Pharmacology.

[88]  P. Neuvonen,et al.  Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance , 2003, Clinical pharmacology and therapeutics.

[89]  Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. , 2003, The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique.

[90]  Paul B. Watkins,et al.  Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug–Drug Interaction , 2003, Circulation.

[91]  L. Waskell,et al.  The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[92]  Yuichi Sugiyama,et al.  Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.

[93]  Yuichi Sugiyama,et al.  Polymorphisms of OATP‐C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics , 2003, Clinical pharmacology and therapeutics.

[94]  M. Affrime,et al.  Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil. , 2004, International journal of clinical pharmacology and therapeutics.

[95]  Miranda R Andrus,et al.  Oral Anticoagulant Drug Interactions with Statins: Case Report of Fluvastatin and Review of the Literature , 2004, Pharmacotherapy.

[96]  R. Schlienger,et al.  Rhabdomyolysis in Association with Simvastatin and Amiodarone , 2004, The Annals of pharmacotherapy.

[97]  Richard Platt,et al.  Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. , 2004, JAMA.

[98]  Steffen Bauer,et al.  Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.

[99]  G. Dresser,et al.  Interactions Between Grapefruit Juice and Cardiovascular Drugs , 2004, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[100]  P. Neuvonen,et al.  Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. , 2004, British journal of clinical pharmacology.

[101]  P. Pentikäinen,et al.  Rhabdomyolysis associated with concomitant use of simvastatin and clarithromycin , 2004, The Annals of pharmacotherapy.

[102]  M. Eisenberg,et al.  Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors☆ , 2004 .

[103]  P. Neuvonen,et al.  High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). , 2004, Pharmacogenetics.

[104]  Helen Pilmore,et al.  Potentially fatal interaction between diltiazem and statins. , 2004, Annals of internal medicine.

[105]  Paul D. Martin,et al.  The effect of gemfibrozil on the pharmacokinetics of rosuvastatin , 2004, Clinical pharmacology and therapeutics.

[106]  J. Paolini,et al.  Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans , 2004, Journal of clinical pharmacology.

[107]  P. Neuvonen,et al.  Pharmacokinetics and Pharmacodynamics of Pravastatin in Pediatric and Adolescent Cardiac Transplant Recipients on a Regimen of Triple Immunosuppression , 2004, Clinical pharmacology and therapeutics.

[108]  U. Hofmann,et al.  Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[109]  Y. Sugiyama,et al.  Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil , 2004, Journal of Pharmacology and Experimental Therapeutics.

[110]  H. Yamada,et al.  Pharmacokinetic and pharmacodynamic interactions between simvastatin and diltiazem in patients with hypercholesterolemia and hypertension. , 2004, Life sciences.

[111]  Eiji Uchida,et al.  Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. , 2004, British journal of clinical pharmacology.

[112]  P. Neuvonen,et al.  Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. , 2004, British journal of clinical pharmacology.

[113]  A. Åsberg,et al.  Substantially elevated levels of atorvastatin and metabolites in cyclosporine‐treated renal transplant recipients , 2004, Clinical pharmacology and therapeutics.

[114]  M. Eisenberg,et al.  Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. , 2004, American heart journal.

[115]  T. Sakaeda,et al.  Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors , 2004, Xenobiotica; the fate of foreign compounds in biological systems.

[116]  M. Endres,et al.  Statin-associated rhabdomyolysis triggered by grapefruit consumption , 2004, Neurology.

[117]  R. Kim,et al.  3‐Hydroxy‐3‐methylglutaryl–coenzyme a Reductase Inhibitors (statins) and Genetic Variability (Single Nucleotide Polymorphisms) in a Hepatic Drug Uptake Transporter: What's it all About? , 2004, Clinical pharmacology and therapeutics.

[118]  P. Neuvonen,et al.  Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. , 2003, British journal of clinical pharmacology.

[119]  E. Wang,et al.  HMG-CoA Reductase Inhibitors (Statins) Characterized as Direct Inhibitors of P-Glycoprotein , 2001, Pharmaceutical Research.

[120]  Paul D. Martin,et al.  Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.

[121]  T. Cuddy,et al.  An open‐label study on the pharmacokinetics (PK) of pitavastatin (NK‐104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers , 2004 .

[122]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[123]  K. Kivistö,et al.  Rhabdomyolysis in a patient receiving atorvastatin and fluconazole , 2005, European Journal of Clinical Pharmacology.

[124]  H. Kusuhara,et al.  Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. , 2004, Drug metabolism and pharmacokinetics.

[125]  Mikko Niemi,et al.  Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics , 2005, Clinical pharmacology and therapeutics.

[126]  P. Neuvonen,et al.  Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone , 2005, Clinical pharmacology and therapeutics.

[127]  P. Neuvonen,et al.  Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. , 2005, British journal of clinical pharmacology.

[128]  P. Neuvonen,et al.  Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.

[129]  R. Tirona.  Ethnic differences in statin disposition , 2005, Clinical pharmacology and therapeutics.

[130]  Michael Schachter,et al.  Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update , 2005, Fundamental & clinical pharmacology.

[131]  T. Sakaeda,et al.  Effects of Acid and Lactone Forms of Eight HMG-CoA Reductase Inhibitors on CYP-Mediated Metabolism and MDR1-Mediated Transport , 2005, Pharmaceutical Research.

[132]  J. Xu,et al.  DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1 , 2005, Drug Metabolism and Disposition.

[133]  P. Neuvonen,et al.  Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects. , 2005, British journal of clinical pharmacology.

[134]  G. Miller,et al.  Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. , 2005, Circulation.

[135]  Caroline A. Lee,et al.  Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment , 2005, Clinical pharmacology and therapeutics.

[136]  Kazuya Maeda,et al.  Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.

[137]  P. Neuvonen,et al.  Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8. , 2005, Basic & clinical pharmacology & toxicology.

[138]  P. Neuvonen,et al.  Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites , 2005, Clinical pharmacology and therapeutics.

[139]  J. Paolini,et al.  Ezetimibe , 2005, Clinical pharmacokinetics.

[140]  Y Vanrenterghem,et al.  Combined Therapy with Atorvastatin and Calcineurin Inhibitors: No Interactions with Tacrolimus , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[141]  D. Oh,et al.  Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers , 2005, Clinical pharmacology and therapeutics.

[142]  E. Wolfel,et al.  Drug therapy in the heart transplant recipient: Part III: common medical problems. , 2005, Circulation.

[143]  U. Hofmann,et al.  Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17 , 2005, Pharmacogenetics and genomics.

[144]  R. Kim,et al.  Transporters and drug therapy: Implications for drug disposition and disease , 2005, Clinical pharmacology and therapeutics.

[145]  S. Kaneko,et al.  Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. , 2005, British journal of clinical pharmacology.

[146]  K. Maeda,et al.  Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin , 2005, Journal of Pharmacology and Experimental Therapeutics.

[147]  Yuichi Sugiyama,et al.  Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.

[148]  M. Davidson,et al.  Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. , 2005, The American journal of cardiology.

[149]  D. Keppler,et al.  Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells , 2005, Molecular Pharmacology.

[150]  Paul D. Martin,et al.  Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics , 2005, Journal of clinical pharmacology.

[151]  P. Poirier,et al.  Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. , 2006, The Canadian journal of cardiology.

[152]  J. Paolini,et al.  Interaction of Single‐Dose Ezetimibe and Steady‐State Cyclosporine in Renal Transplant Patients , 2006, Journal of clinical pharmacology.

[153]  A. D. Rodrigues,et al.  GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS , 2006, Drug Metabolism and Disposition.

[154]  P. Neuvonen,et al.  Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics , 2006, Pharmacogenetics and genomics.

[155]  T. Edeki,et al.  Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects. , 2006, Clinical therapeutics.

[156]  J. Paolini,et al.  Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects , 2006, Journal of clinical pharmacology.

[157]  P. Neuvonen,et al.  The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone , 2006, European Journal of Clinical Pharmacology.

[158]  R. Kim,et al.  Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. , 2006, Gastroenterology.

[159]  Alicja R Rudnicka,et al.  Statin safety: a systematic review. , 2006, The American journal of cardiology.

[160]  K. Maeda,et al.  DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.

[161]  P. Neuvonen,et al.  SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin , 2006, Clinical pharmacology and therapeutics.

[162]  Yuichi Sugiyama,et al.  Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.

[163]  P. Neuvonen,et al.  Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide , 2006, European Journal of Clinical Pharmacology.

[164]  Mikko Niemi,et al.  SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid , 2006, Pharmacogenetics and genomics.

[165]  H. Bays.  Statin safety: an overview and assessment of the data--2005. , 2006, The American journal of cardiology.